KNSA

Peers: CRDL BCRX ALKS CYTK MIRM KRYS ARGX REGN PTCT ACAD

| Held by: IWM VTI VB VBK IWO DFAS VTWO DFAC PSC VHT

Index	RUT
Market Cap	7.11B
Enterprise Value	6.55B
Income	109.57M
Sales	945.96M
Book/sh	9.05
Cash/sh	7.24
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	366
IPO	May 24, 2018

P/E	69.06
Forward P/E	44.69
PEG	0.80
P/S	7.52
P/B	10.00
P/C	12.50
P/FCF	36.07
EV/EBITDA	49.50
EV/Sales	6.93
Quick Ratio	3.35
Current Ratio	3.91
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	1.31
EPS next Y	2.03
EPS next Q	0.25
EPS this Y	97.88%
EPS next Y	36.47%
EPS next 5Y	55.96%
EPS past 3/5Y	-34.04% -
Sales past 3/5Y	45.45% -
EPS Y/Y TTM	192.34%
Sales Y/Y TTM	58.19%
EPS Q/Q	142.08%
Sales Q/Q	58.12%
Earnings	Oct 27 BMO
EPS/Sales Surpr.	50.94% 9.71%

Insider Own	42.05%
Insider Trans	-2.20%
Inst Own	60.55%
Inst Trans	1.94%
ROA	12.92%
ROE	17.59%
ROIC	15.34%
Gross Margin	54.21%
Oper. Margin	13.79%
Profit Margin	11.58%
SMA20	6.95%
SMA50	12.83%
SMA200	47.77%
Trades

Shs Outstand	48.75M
Shs Float	45.53M
Short Float	8.27%
Short Ratio	5.90
Short Interest	3.76M
52W High	98.48 -8.08%
52W Low	37.02 144.52%
Volatility	5.18% 5.07%
ATR (14)	4.76
RSI (14)	57.24
Beta	0.08
Rel Volume	1.04
Avg Volume	637.43K
Volume	361,716

Perf Week	-7.22%
Perf Month	16.11%
Perf Quarter	19.01%
Perf Half Y	59.00%
Perf YTD	119.44%
Perf Year	131.27%
Perf 3Y	458.77%
Perf 5Y	514.53%
Perf 10Y	-
Recom	1.00
Target Price	109.43
Prev Close	96.12
Price	90.52
Change %	-5.83%

Consensus

Strong Buy

Avg. Price Target

$109.43

Implied Upside

+20.9%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 30, 2026	Initiated	WWells Fargo	Overweight	$87	-3.9%
Feb 19, 2026	Initiated	CCanaccord Genuity	Buy	$62	-31.5%
Sep 29, 2025	Initiated	TTD Cowen	Buy	$60	-33.7%
Mar 13, 2025	Initiated	CCitigroup	Buy	$40	-55.8%
Sep 13, 2024	Initiated	JJefferies	Buy	$40	-55.8%
May 03, 2024	Initiated	WWells Fargo	Overweight	$34	-62.4%
Jun 29, 2020	Reiterated	BBofA Securities	Buy	$25 → $40	-55.8%
Apr 01, 2020	Initiated	BBofA/Merrill	Buy	$25	-72.4%
Mar 11, 2019	Initiated	BBarclays	Overweight	$26	-71.3%
Dec 12, 2018	Reiterated	WWedbush	Outperform	$31 → $33	-63.5%
Jun 19, 2018	Initiated	JJMP Securities	Mkt Outperform	$33	-63.5%

Oct-27-26 10:40AM	Kiniksa Crushes Estimates As ARCALYST Crosses $1 Billion Run-Rate, But Guidance Implies A Costlier, Slower Q4 (Earnings Whispers) +22.23%
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-22-26 07:34PM	Kiniksa's Raised Outlook Implies A Bigger Third Quarter Than Wall Street Is Modeling (Earnings Whispers) -5.03%
04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026 (GlobeNewswire)
Oct-21-26 08:24AM	Dow Jones Futures Rise As SpaceX, Supermicro Revive AI Stocks; Tesla, Meta On Deck (Investor's Business Daily)
07:34AM	Loading…
Oct-14-26 07:34AM	Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight (Investor's Business Daily)
Sep-04-26 04:01PM	Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
Aug-07-26 04:01PM	Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
Jul-28-26 10:09AM	Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance (InvestorsHub) +25.03%
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-27-26 09:23AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2026: Everything You Need To Know Ahead Of ... (GuruFocus.com)
Jul-23-26 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 (GlobeNewswire)
Jun-23-26 03:14PM	Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View (Investor's Business Daily)
03:03PM	Biotech Kiniska Pushes Toward A Buy Zone With Blockbuster Drug Sales In View (Investor's Business Daily)
May-29-26 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
03:05AM	Loading…
Apr-29-26 03:05AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ... (GuruFocus.com)
Apr-28-26 07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution (GlobeNewswire) +23.48%
Apr-23-26 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 (GlobeNewswire)
Apr-08-26 08:00AM	Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST (rilonacept) in Recurrent Pericarditis (GlobeNewswire)
Apr-06-26 04:27PM	Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market (Investor's Business Daily)
Mar-04-26 01:35PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily)
Feb-26-26 08:37AM	Kiniksa price target raised to $53 from $50 at Wedbush (TipRanks)
Feb-25-26 08:17PM	Nurix Therapeutics Stock Sees RS Rating Jump To 82 (Investor's Business Daily)
04:01PM	Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-24-26 04:01PM	Kiniksa Pharmaceuticals International PLC (KNSA) Q4 2025 Earnings Call Highlights: Record ... (GuruFocus.com) -8.21%
12:49PM	Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Feb-23-26 04:48PM	Do Options Traders Know Something About KNSA Stock We Don't? (Zacks)
07:20AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
04:01PM	Loading…
Feb-19-26 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
10:00AM	Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:40AM	Shopify, eBay upgraded: Wall Street's top analyst calls (The Fly)
Feb-17-26 10:00AM	Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-12-26 07:30AM	Kiniksa Pharmaceuticals Provides Corporate Update (GlobeNewswire)
Jan-07-26 04:01PM	Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-25 06:50AM	Why Analysts Favor Kiniksa Pharmaceuticals (KNSA) (Insider Monkey)
Nov-12-25 04:01PM	Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-30-25 08:25AM	New Strong Sell Stocks for Oct. 30th (Zacks)
Oct-28-25 08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-27-25 09:28AM	Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KNSA) Reports Q3 2025 Result (GuruFocus.com)
Oct-23-25 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 (GlobeNewswire)
Oct-17-25 08:00AM	Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis (GlobeNewswire)
Oct-16-25 12:10PM	Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again (Zacks)
Oct-14-25 09:55AM	Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet (Zacks)
Oct-06-25 09:50AM	GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal (Zacks)
08:50AM	Here's What Could Help Kiniksa Pharmaceuticals International, plc (KNSA) Maintain Its Recent Price Strength (Zacks)
Sep-29-25 08:06AM	Beat the Market the Zacks Way: Helios Technologies, InterDigital, UnitedHealth in Focus (Zacks) +6.25%
Sep-26-25 10:05AM	CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program (Zacks)
Sep-25-25 11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 11:06AM	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug (Zacks)
04:47AM	Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience (Zacks)
Sep-23-25 09:23AM	5 Biotech Stocks Worth Adding to Your Portfolio Now (Zacks)
Sep-22-25 12:03PM	SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU (Zacks)
11:29AM	FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing (Zacks)
Sep-19-25 08:50AM	Kiniksa Pharmaceuticals International, plc (KNSA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Sep-15-25 09:52AM	Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain (Zacks)
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
Sep-04-25 11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 10:02AM	Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results (Zacks)
09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why (Zacks)
Sep-02-25 09:02AM	Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA? (Zacks)
Sep-01-25 10:50AM	ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win (Zacks)
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks)
Aug-28-25 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 11:16AM	Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin (Zacks)
Aug-25-25 11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
Aug-18-25 09:55AM	Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade (Zacks)
08:50AM	Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Aug-14-25 09:08AM	Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas (Zacks)
Aug-13-25 12:31PM	Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
07:39AM	5 Stocks With Recent Price Strength Amid Trade & Rate Cut Uncertainties (Zacks)
Aug-05-25 12:00PM	Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know (Zacks)
Aug-01-25 01:32PM	Just The Tonic: This Medical Stock, A Mutual Fund Darling, Tests Entry Amid 58% Run (Investor's Business Daily) +5.68%
12:20PM	Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge (Zacks)
09:55AM	Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect? (Zacks)
08:50AM	Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going (Zacks)
Jul-30-25 03:11AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... (GuruFocus.com)
Jul-29-25 08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates (Zacks) +12.32%
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-28-25 09:29AM	Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KNSA) Reports Q2 2025 Result (GuruFocus.com)
Jul-24-25 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire)
Jul-03-25 08:42AM	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore (Zacks)
Jul-02-25 07:00PM	Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth (Motley Fool)
09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 01:38PM	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind (Investor's Business Daily)
01:37PM	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind (Investor's Business Daily)
Jun-05-25 07:00AM	Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis (GlobeNewswire)
May-29-25 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-05-25 04:51PM	Kiniksa Pharmaceuticals: Making Steady Progress (Seeking Alpha)
Apr-30-25 08:30AM	Kiniksa Pharmaceuticals Announces GRAMMY Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis (GlobeNewswire)
Apr-29-25 03:07PM	Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript (Seeking Alpha) +20.54%
08:35AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Sanj K	CHAIRMAN & CEO	Nov 03 '26	Option Exercise	11.71	130,326	1,525,623	1,000,207	Nov 03 07:30 PM
Patel Sanj K	CHAIRMAN & CEO	Nov 02 '26	Option Exercise	8.83	53,381	471,354	959,314	Nov 03 07:30 PM
Patel Sanj K	CHAIRMAN & CEO	Oct 30 '26	Option Exercise	8.83	47,530	419,690	999,324	Nov 03 07:30 PM
Patel Sanj K	CHAIRMAN & CEO	Nov 03 '26	Sale	93.27	220,170	20,535,459	780,037	Nov 03 07:30 PM
Patel Sanj K	CHAIRMAN & CEO	Oct 30 '26	Sale	93.12	92,891	8,649,772	905,933	Nov 03 07:30 PM
Patel Sanj K	CHAIRMAN & CEO	Nov 02 '26	Sale	91.86	89,433	8,215,096	869,881	Nov 03 07:30 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Nov 02 '26	Option Exercise	13.04	36,783	479,738	57,637	Nov 03 06:32 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Nov 02 '26	Sale	92.16	36,783	3,389,975	20,854	Nov 03 06:32 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Oct 30 '26	Option Exercise	24.38	77,587	1,891,829	147,509	Nov 03 06:28 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Nov 02 '26	Option Exercise	22.48	18,413	413,941	88,335	Nov 03 06:28 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Oct 30 '26	Sale	93.02	77,587	7,217,397	69,922	Nov 03 06:28 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Nov 02 '26	Sale	93.39	18,413	1,719,670	69,922	Nov 03 06:28 PM
Moat Ross	CHIEF OPERATING OFFICER	Oct 30 '26	Option Exercise	13.74	69,595	956,534	85,902	Nov 03 06:27 PM
Moat Ross	CHIEF OPERATING OFFICER	Nov 02 '26	Option Exercise	20.77	27,977	581,155	38,271	Nov 03 06:27 PM
Moat Ross	CHIEF OPERATING OFFICER	Oct 30 '26	Sale	93.13	75,608	7,041,735	10,294	Nov 03 06:27 PM
Moat Ross	CHIEF OPERATING OFFICER	Nov 02 '26	Sale	92.36	27,977	2,584,055	10,294	Nov 03 06:27 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Oct 30 '26	Option Exercise	12.70	19,895	252,585	48,957	Nov 03 06:26 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Oct 30 '26	Sale	94.43	36,260	3,424,091	12,697	Nov 03 06:26 PM
Ragosa Mark	Officer	Nov 02 '26	Proposed Sale	92.16	36,783	3,390,075		Nov 02 05:13 PM
Patel Sanj K	Officer	Oct 30 '26	Proposed Sale	93.12	553,794	51,571,367		Oct 30 06:20 PM
Moat Ross	Officer	Oct 30 '26	Proposed Sale	94.16	103,585	9,753,812		Oct 30 06:15 PM
Megna Michael R	Officer	Oct 30 '26	Proposed Sale	95.91	47,540	4,559,561		Oct 30 06:14 PM
Paolini John F.	Officer	Oct 30 '26	Proposed Sale	93.02	96,000	8,930,275		Oct 30 06:13 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Sep 03 '26	Sale	80.30	4,600	369,380	29,062	Sep 03 04:40 PM
Megna Michael R	Officer	Sep 03 '26	Proposed Sale	80.30	4,600	369,380		Sep 03 04:02 PM
Cole G Bradley	Director	Jul 29 '26	Sale	81.43	3,673	299,092	11,672	Jul 31 04:34 PM
Tessari Eben	Former Affiliate	Jul 29 '26	Proposed Sale	79.74	67,062	5,347,344		Jul 29 04:03 PM
Cole G Bradley	Director	Jul 29 '26	Proposed Sale	81.43	3,673	299,092		Jul 29 04:02 PM
Paolini John F.	CHIEF MEDICAL OFFICER	May 01 '26	Option Exercise	10.36	58,424	605,273	124,047	May 05 04:54 PM
Paolini John F.	CHIEF MEDICAL OFFICER	May 01 '26	Sale	53.71	58,424	3,137,823	65,623	May 05 04:54 PM
Paolini John F.	Officer	May 01 '26	Proposed Sale	53.71	58,424	3,137,710		May 01 04:45 PM
Patel Sanj K	CHAIRMAN & CEO	May 01 '26	Option Exercise	30.93	48,565	1,502,115	48,565	May 01 04:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 01 '26	Sale	54.02	48,565	2,623,481	0	May 01 04:32 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 28 '26	Option Exercise	12.56	483,654	6,075,153	483,654	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 29 '26	Option Exercise	30.93	22,544	697,286	22,544	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 30 '26	Option Exercise	30.93	2,141	66,221	2,141	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 28 '26	Sale	51.86	483,654	25,081,991	0	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 29 '26	Sale	54.01	22,544	1,217,601	0	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 30 '26	Sale	54.01	2,141	115,635	0	Apr 30 06:33 PM
Quart Barry D	Director	Apr 28 '26	Option Exercise	14.33	13,099	187,709	25,645	Apr 29 04:46 PM
Quart Barry D	Director	Apr 28 '26	Sale	50.10	13,099	656,260	12,546	Apr 29 04:46 PM
Patel Sanj K	Officer	Apr 28 '26	Proposed Sale	51.60	344,591	17,780,309		Apr 28 04:49 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Apr 09 '26	Sale	46.69	6,625	309,321	27,418	Apr 13 04:35 PM
Moat Ross	CHIEF OPERATING OFFICER	Apr 09 '26	Sale	46.69	1,703	79,513	12,029	Apr 13 04:34 PM
Moat Ross	Officer	Apr 09 '26	Proposed Sale	46.69	1,703	79,513		Apr 09 04:03 PM
Megna Michael R	Officer	Apr 09 '26	Proposed Sale	46.69	6,625	309,321		Apr 09 04:02 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 06 '26	Option Exercise	10.36	7,278	75,400	7,278	Apr 08 04:43 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 06 '26	Sale	50.01	7,278	363,973	0	Apr 08 04:43 PM
Moat Ross	CHIEF OPERATING OFFICER	Apr 06 '26	Sale	48.58	2,367	114,989	12,029	Apr 08 04:39 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Apr 07 '26	Option Exercise	1.00	3,932	3,932	35,709	Apr 08 04:38 PM
Quart Barry D	Director	Apr 06 '26	Option Exercise	14.33	6,901	98,891	19,447	Apr 08 04:34 PM
Quart Barry D	Director	Apr 06 '26	Sale	50.00	6,901	345,050	12,546	Apr 08 04:34 PM
Quart Barry D	Director	Apr 06 '26	Proposed Sale	50.00	20,000	1,000,000		Apr 06 04:55 PM
Patel Sanj K	Officer	Apr 06 '26	Proposed Sale	50.00	219,591	10,979,550		Apr 06 04:54 PM
Moat Ross	Officer	Apr 06 '26	Proposed Sale	48.58	2,367	114,989		Apr 06 04:04 PM
Ragosa Mark	Officer	Mar 09 '26	Proposed Sale	45.92	36,722	1,686,179		Mar 09 05:24 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Mar 02 '26	Option Exercise	10.36	40,000	414,400	101,324	Mar 04 04:40 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Mar 02 '26	Sale	44.82	40,000	1,792,940	61,324	Mar 04 04:40 PM
Paolini John F.	Officer	Mar 02 '26	Proposed Sale	44.82	40,000	1,792,970		Mar 02 05:22 PM
Quart Barry D	Director	Feb 12 '26	Option Exercise	15.47	2,690	41,614	15,236	Feb 12 04:34 PM
Quart Barry D	Director	Feb 10 '26	Option Exercise	15.47	110	1,702	12,656	Feb 12 04:34 PM
Quart Barry D	Director	Feb 12 '26	Sale	45.00	2,690	121,050	12,546	Feb 12 04:34 PM
Quart Barry D	Director	Feb 10 '26	Sale	45.00	110	4,950	12,546	Feb 12 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Feb 09 '26	Option Exercise	13.87	10,845	150,371	29,931	Feb 11 04:38 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Feb 09 '26	Sale	43.28	17,845	772,254	12,086	Feb 11 04:38 PM
Quart Barry D	Director	Feb 03 '26	Option Exercise	15.47	12,528	193,808	25,074	Feb 04 06:24 PM
Quart Barry D	Director	Feb 04 '26	Option Exercise	15.47	2,602	40,253	15,148	Feb 04 06:24 PM
Quart Barry D	Director	Feb 02 '26	Option Exercise	15.47	830	12,840	13,376	Feb 04 06:24 PM
Quart Barry D	Director	Feb 03 '26	Sale	45.27	12,528	567,143	12,546	Feb 04 06:24 PM
Quart Barry D	Director	Feb 04 '26	Sale	45.02	2,602	117,142	12,546	Feb 04 06:24 PM
Quart Barry D	Director	Feb 02 '26	Sale	45.00	830	37,350	12,546	Feb 04 06:24 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jan 08 '26	Sale	41.89	12,000	502,680	19,086	Jan 09 04:35 PM
Quart Barry D	Director	Dec 15 '25	Option Exercise	10.36	20,129	208,536	32,675	Dec 17 04:38 PM
Quart Barry D	Director	Dec 15 '25	Sale	41.51	20,129	835,555	12,546	Dec 17 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Dec 15 '25	Option Exercise	8.83	6,000	52,980	28,714	Dec 17 04:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	Dec 15 '25	Sale	41.56	12,048	500,715	16,666	Dec 17 04:37 PM
Quart Barry D	Director	Dec 15 '25	Proposed Sale	41.51	58,889	2,444,530		Dec 15 05:13 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 08 '25	Option Exercise	11.34	42,841	486,025	73,927	Dec 10 05:06 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 08 '25	Sale	41.49	42,841	1,777,473	31,086	Dec 10 05:06 PM
Ragosa Mark	Officer	Dec 08 '25	Proposed Sale	41.49	72,686	3,015,917		Dec 08 05:06 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 26 '25	Option Exercise	22.89	200	4,578	22,914	Dec 01 04:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 26 '25	Sale	42.89	200	8,578	22,714	Dec 01 04:37 PM
Tessari Eben	Officer	Nov 26 '25	Proposed Sale	42.89	48,384	2,075,190		Nov 26 05:24 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 17 '25	Option Exercise	8.83	6,500	57,395	35,184	Nov 19 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 17 '25	Sale	41.24	12,470	514,224	22,714	Nov 19 04:38 PM
Tessari Eben	Officer	Nov 17 '25	Proposed Sale	41.24	12,470	514,225		Nov 17 05:07 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Nov 12 '25	Option Exercise	30.93	19,900	615,507	50,986	Nov 14 04:35 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Nov 12 '25	Sale	40.94	19,900	814,706	31,086	Nov 14 04:35 PM

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

CEO & Chairman of the BoardMr. Sanjiv K. Patel

M.D.Dr. John F. Paolini FACC

ConsultantMr. Eben Tessari

Senior VP & Chief Accounting OfficerMr. Michael R. Megna CPA

Senior VP & Chief Technical OfficerMs. Mei Jang

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Kiniksa Pharmaceuticals International Plc

Upgrade your Finviz experience